Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) lost more half its value Monday after reporting data from the Phase IIb AURA-LV study of voclosporin ( LX211) to treat active lupus nephritis (LN). Although
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury